With AI, it's now possible for researchers to predict the three-dimensional structures of proteins directly from their amino-acid sequences. But what biologists really want to predict, says Columbia ...

ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

A team from University of Toronto Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell—a new approach to drug discovery that has already yielded some promising ...

The mechanism of action of mRNA vaccines goes far beyond harnessing host cellular machinery to produce antigenic proteins to spur immunity, write Nicolas Hulscher, M.P.H., Peter A. McCullough, M.D., M ...

Nonsense-mediated mRNA decay (NMD) is one of the most important processes in our cells to ensure that no faulty or incomplete proteins are produced. Scientists have now identified a central mechanism ...

The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The ...

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.

Double-stranded RNA (dsRNA) is a critical immunostimulatory impurity in mRNA production and poses a problem for the downstream purification methods vital to manufacturing mRNA vaccines and ...

In high-risk melanoma patients who had undergone complete tumor removal, adding Moderna's mRNA-4157 to Keytruda reduced the risk of recurrence or death by 49% versus Keytruda alone. The combination ...